10-Q: Tivic Health Systems Reports Q3 2024 Results, Focuses on Vagus Nerve Stimulation Research

Tivic Health Systems reported a decrease in revenue for the third quarter of 2024 compared to the same period last year, while also highlighting progress in their vagus nerve stimulation research and cost reduction efforts.

Summary

• Tivic Health Systems reported a net loss of $1.43 million for the three months ended September 30, 2024, and a net loss of $4.18 million for the nine months ended September 30, 2024.
• Revenue for the third quarter was $126,000, a decrease of 56% compared to $282,000 in the same period of 2023, primarily due to a decrease in unit sales.
• Revenue for the nine months ended September 30, 2024 was $600,000, a decrease of 27% compared to $819,000 in the same period of 2023, primarily due to a decrease in unit sales.
• The company's cash and cash equivalents were $2.2 million as of September 30, 2024.
• Tivic Health is focusing on its vagus nerve stimulation (VNS) platform, with ongoing clinical research and a partnership to develop a commercial strategy.
• The company terminated its office lease and fulfillment services agreement to reduce costs.
• Tivic Health has raised additional capital through equity offerings and an equity distribution agreement.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in research and cost reduction, the significant revenue decline, net losses, and going concern uncertainty weigh heavily on the overall sentiment. The need for additional capital and the Nasdaq delisting risk further contribute to a negative outlook.

Positives

• Tivic Health's non-invasive cervical vagus nerve stimulation (ncVNS) approach showed promising results in a pilot study, with a 97% increase in heart rate variability.
• The company is actively working on a commercial strategy for its ncVNS technology through a partnership with Fletcher Spaght, Inc.
• Tivic Health has reduced operating expenses by terminating its office lease and fulfillment services agreement.
• The company has established in-house assembly and testing capabilities, reducing reliance on third-party services.
• Tivic Health has secured additional funding through equity offerings and an equity distribution agreement.

Negatives

• Tivic Health experienced a significant decrease in revenue, with a 56% drop in Q3 2024 compared to Q3 2023.
• The company reported a net loss of $4.18 million for the nine months ended September 30, 2024.
• Tivic Health's cash and cash equivalents were $2.2 million as of September 30, 2024, raising concerns about its ability to continue as a going concern.
• The company received a notification from Nasdaq for not meeting the minimum bid price requirement, which could lead to delisting.
• The company has a history of operating losses and negative cash flows since its inception.

Risks

• Tivic Health's ability to continue as a going concern is uncertain due to its current cash levels and burn rate.
• The company's stock price is below $1.00, which could lead to delisting from the Nasdaq Capital Market.
• The company is dependent on raising additional capital to fund its operations and research and development.
• Global supply chain issues, inflation, and geopolitical tensions could negatively impact the company's operations and financial results.
• The company's ability to generate significant revenue from product sales is uncertain.
• The company faces risks associated with the development and commercialization of new products, including regulatory approvals and market adoption.

Future Outlook

Tivic Health plans to increase its research and development investments in its vagus nerve platform and clinical applications in 2024. The company expects to continue to incur losses for the foreseeable future as it expands its research and development activities and works towards commercialization of new products. The company will need to raise additional capital to continue operating its business and fund its planned operations.

Management Comments

• The company is focusing on its vagus nerve stimulation (VNS) platform, with ongoing clinical research and a partnership to develop a commercial strategy.
• The company terminated its office lease and fulfillment services agreement to reduce costs.
• Tivic Health has raised additional capital through equity offerings and an equity distribution agreement.

Industry Context

The bioelectronic medicine market is an emerging space, and Tivic Health is positioning itself as a player in non-invasive neuromodulation. The company's focus on vagus nerve stimulation aligns with a growing interest in this area for treating various conditions. The company's challenges in revenue growth and profitability are not uncommon for companies in this stage of development in the medical device industry.

Comparison to Industry Standards

• Tivic Health's revenue decline of 56% in Q3 2024 is concerning compared to industry standards, where growth is typically expected for companies with FDA-approved products.
• The company's net loss of $4.18 million for the nine months ended September 30, 2024, is significant and indicates a need for improved financial performance.
• The company's cash position of $2.2 million raises concerns about its ability to fund operations and research, which is a common challenge for early-stage medical device companies.
• The positive results from the ncVNS pilot study are promising and could differentiate Tivic Health from competitors in the neuromodulation space, such as electroCore and SetPoint Medical, which are also developing non-invasive VNS therapies.
• The partnership with Fletcher Spaght, Inc. is a positive step towards developing a commercial strategy, which is crucial for long-term success in the competitive medical device market.
• The cost-cutting measures, such as terminating the office lease and fulfillment agreement, are necessary steps to improve financial stability, which is a common practice for companies facing financial challenges.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings and the risk of delisting from Nasdaq.
• Employees may be affected by cost-cutting measures and potential changes in the company's operations.
• Customers may experience changes in product availability and support due to the transition to new logistics providers.
• Suppliers may be affected by the company's cost-cutting measures and changes in its supply chain.
• Creditors face increased risk due to the company's financial challenges and going concern uncertainty.

Next Steps

• The company will continue to focus on its vagus nerve stimulation (VNS) platform, with ongoing clinical research.
• The company will work with Fletcher Spaght, Inc. to develop a commercial strategy for its ncVNS technology.
• The company will continue to monitor its stock price and consider options to regain compliance with the Nasdaq minimum bid price requirement.
• The company will continue to seek additional funding to support its operations and research and development.
• The company will continue to monitor the impact of global economic factors on its business.

Key Dates

Keywords

vagus nerve stimulation, bioelectronic medicine, ClearUP, neuromodulation, sinus pain, revenue, clinical research, equity offering, cost reduction, Nasdaq